Earlier this month, Calyxo, Inc. announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo is a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions. The company has developed the innovative CVAC Aspiration System, which utilizes irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome, a result that historically  has been difficult to achieve consistently. The Series C financing will fund further product development and the expansion of Calyxo's team.

Newly released results of a nationwide study published in the Journal of Urology indicate that more than five million Americans will pass a kidney stone in 2022, a number that is expected to grow. Kidney stone disease is a painful condition that brings with it staggering healthcare costs that Current Urology Reports estimates will reach $4.1 billion in yearly direct treatment costs by 2030. Existing kidney stone treatments do not reliably remove all the stone pieces. According to clinical studies published in Urology and the Journal of Urology, residual fragments left behind are associated with a 20% to 44% rate of problems including pain, infection, emergency department visits, hospitalization, and need for retreatment, demonstrating the compelling need for innovation in this space.

"We are excited to be moving into the next step of our evolution," according to Joe Catanese, President and CEO of Calyxo, which has been headquartered at Hacienda since May 2020.  "Kidney stone disease is a painful problem for patients, and it consumes vast amounts of healthcare resources each year. We believe our solutions will better meet the needs of kidney stone patients and transform the care of this condition. We look forward to applying this latest financing round toward further product development and the expansion of our team."

Catanese previously co-founded NeoTract, which developed and commercialized the FDA-cleared UroLift System, a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. NeoTract was successfully acquired by Teleflex in 2017 in a transaction valued at over $1 billion. For Calyxo, Catanese has assembled a team and board that include many of NeoTract's founding team and key players. 

"We are proud to invest in Calyxo and its groundbreaking kidney stone treatment technology," says Ryan Drant, Founder and Managing Partner of Questa Capital and Calyxo board member. "The company's leadership team has a remarkable track record of recognizing significant unmet physician and patient needs within urology and bringing to market game-changing solutions to meet those needs. We look forward to supporting Calyxo through forthcoming development and commercialization milestones, and we are excited to see the team expand."

"Calyxo has an opportunity to alter the kidney stone treatment category and deliver a new generation of devices that can reliably improve care for millions of people afflicted by kidney stones," according to Luke Düster, Chief Investment Officer of CRG. "We are proud to support this team as it accomplishes its mission to provide a genuine solution for a long-standing medical problem."

For more information about Calyxo, please visit calyxoinc.com.